Read-Gene Statistics

Total Valuation

Read-Gene has a market cap or net worth of PLN 55.88 million. The enterprise value is 57.68 million.

Market Cap	55.88M
Enterprise Value	57.68M

Important Dates

The next estimated earnings date is Monday, August 11, 2025.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Read-Gene has 11.79 million shares outstanding.

Current Share Class	1.49M
Shares Outstanding	11.79M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	7.16%
Owned by Institutions (%)	n/a
Float	1.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.86
PB Ratio	16.68
P/TBV Ratio	16.68
P/FCF Ratio	n/a
P/OCF Ratio	71.88
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-97.60
EV / Sales	3.98
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.20, with a Debt / Equity ratio of 2.36.

Current Ratio	7.20
Quick Ratio	7.19
Debt / Equity	2.36
Debt / EBITDA	108.80
Debt / FCF	n/a
Interest Coverage	-1.20

Financial Efficiency

Return on equity (ROE) is -17.19% and return on invested capital (ROIC) is -2.35%.

Return on Equity (ROE)	-17.19%
Return on Assets (ROA)	-1.75%
Return on Invested Capital (ROIC)	-2.35%
Return on Capital Employed (ROCE)	-2.98%
Revenue Per Employee	805,258
Profits Per Employee	-32,836
Employee Count	29
Asset Turnover	1.02
Inventory Turnover	14.24

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.24% in the last 52 weeks. The beta is 0.68, so Read-Gene's price volatility has been lower than the market average.

Beta (5Y)	0.68
52-Week Price Change	-4.24%
50-Day Moving Average	4.44
200-Day Moving Average	4.84
Relative Strength Index (RSI)	65.27
Average Volume (20 Days)	1,266

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Read-Gene had revenue of PLN 14.49 million and -591,039 in losses. Loss per share was -0.05.

Revenue	14.49M
Gross Profit	13.52M
Operating Income	-395,841
Pretax Income	-591,039
Net Income	-591,039
EBITDA	72,687
EBIT	-395,841
Loss Per Share	-0.05

Full Income Statement

Balance Sheet

The company has 6.11 million in cash and 7.91 million in debt, giving a net cash position of -1.80 million or -0.15 per share.

Cash & Cash Equivalents	6.11M
Total Debt	7.91M
Net Cash	-1.80M
Net Cash Per Share	-0.15
Equity (Book Value)	3.35M
Book Value Per Share	0.28
Working Capital	6.87M

Full Balance Sheet

Cash Flow

Operating Cash Flow	777,492
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 93.25%, with operating and profit margins of -2.73% and -4.08%.

Gross Margin	93.25%
Operating Margin	-2.73%
Pretax Margin	-4.08%
Profit Margin	-4.08%
EBITDA Margin	0.50%
EBIT Margin	-2.73%
FCF Margin	n/a

Dividends & Yields

Read-Gene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-1.06%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Read-Gene has an Altman Z-Score of 4.45 and a Piotroski F-Score of 4.

Altman Z-Score	4.45
Piotroski F-Score	4